• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Bisker-Leib Vered

    1/23/23 9:00:13 PM ET
    $AYLA
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AYLA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Bisker-Leib Vered

    (Last) (First) (Middle)
    OPPENHEIMER 4

    (Street)
    REHOVOT L3 7670104

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Old Ayala, Inc [ AYLA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/19/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $10.98 01/19/2023 D 8,750(1)(2) (3) 08/17/2030 Common Stock 8,750 (2) 0 D
    Stock Option (right to buy) $10.35 01/19/2023 D 6,250(1)(2) (4) 06/09/2031 Common Stock 6,250 (2) 0 D
    Stock Option (right to buy) $1.63 01/19/2023 D 6,250(1)(2) (5) 06/12/2032 Common Stock 6,250 (2) 0 D
    Explanation of Responses:
    1. This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock").
    2. Each outstanding option to purchase Ayala Common Stock (each, an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option.
    3. This option vests or vested and becomes or became exercisable in thirty-six substantially equal monthly installments, such that the option shall be fully vested on August 18, 2023.
    4. This option is fully vested and exercisable.
    5. This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
    /s/ Roni Mamluk, Ph.D., Attorney-in-Fact for Vered Bisker-Leib 01/23/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AYLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYLA

    DatePrice TargetRatingAnalyst
    12/20/2021$22.00Buy
    Maxim Group
    12/20/2021$18.00Buy
    HC Wainwright & Co.
    11/30/2021$12.00 → $17.00Hold → Buy
    Jefferies
    8/17/2021$27.00 → $25.00Outperform
    Oppenheimer
    7/13/2021$29.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ayala Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/20/21 7:55:57 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Ayala Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      12/20/21 6:22:04 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals upgraded by Jefferies with a new price target

      Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously

      11/30/21 6:55:03 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    SEC Filings

    See more
    • SEC Form 10-K filed by Ayala Pharmaceuticals Inc.

      10-K - Old Ayala, Inc (0001797336) (Filer)

      3/31/23 6:38:48 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.

      15-12G - Old Ayala, Inc (0001797336) (Filer)

      1/30/23 3:30:02 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Old Ayala, Inc (0001797336) (Filer)

      1/25/23 4:53:46 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/8/23 5:16:37 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.

      SC 13G - Old Ayala, Inc (0001797336) (Subject)

      2/7/23 6:01:50 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/6/23 2:49:38 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Financials

    Live finance-specific insights

    See more
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) --  Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Advaxis and Ayala Pharmaceuticals Complete Merger

      REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na

      1/19/23 9:37:49 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

      REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten

      11/17/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

      REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec

      11/16/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Martell Bridget A

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:04:06 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Orbach Pini

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:00:56 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Golan Roy

      3 - Old Ayala, Inc (0001797336) (Issuer)

      10/31/23 5:48:50 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary